

Chandra P Prasad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4747007/publications.pdf>

Version: 2024-02-01

43
papers

1,474
citations

304368

22
h-index

315357

38
g-index

43
all docs

43
docs citations

43
times ranked

2265
citing authors

#	ARTICLE	IF	CITATIONS
1	Microarray based gene expression profiling of advanced gall bladder cancer. <i>Experimental Oncology</i> , 2023, 42, 277-284.	0.4	1
2	Quercetin Impairs HuR-Driven Progression and Migration of Triple Negative Breast Cancer (TNBC) Cells. <i>Nutrition and Cancer</i> , 2022, 74, 1497-1510.	0.9	16
3	Mixed Ni(II) and Co(II) complexes of nalidixic acid drug: Synthesis, characterization, DNA/BSA binding profile and in vitro cytotoxic evaluation against MDA-MB-231 and HepG2 cancer cell lines. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2022, 271, 120910.	2.0	11
4	In vitro anticancer efficacy of a polyphenolic combination of Quercetin, Curcumin, and Berberine in triple negative breast cancer (TNBC) cells. <i>Phytomedicine Plus</i> , 2022, 2, 100265.	0.9	9
5	Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis. <i>Breast</i> , 2022, 64, 7-18.	0.9	13
6	Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial. <i>British Journal of Haematology</i> , 2022, 198, 288-297.	1.2	5
7	Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). <i>Trials</i> , 2022, 23, 420.	0.7	6
8	The feasibility of weekly paclitaxel in improving performance status(PS) of advanced non-small cell lung cancer (NSCLC) patients with poor performance status: A single-arm phase two trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21155-e21155.	0.8	0
9	Essential role of aerobic glycolysis in epithelial-to-mesenchymal transition during carcinogenesis. <i>Clinical and Translational Oncology</i> , 2022, 24, 1844-1855.	1.2	9
10	Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis. <i>Molecular Biology Reports</i> , 2021, 48, 4733-4745.	1.0	26
11	Dihydratanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2177-2184.	0.5	12
12	Publication Charges Associated with Quality Open Access (OA) Publishing and Its Impact on Low Middle Income Countries (LMICs), Time to Reframe Research Policies. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2743-2747.	0.5	8
13	Quercetin obstructs Triple Negative Breast Cancer (TNBC) progression by targeting HuR. <i>Planta Medica</i> , 2021, 87, .	0.7	0
14	Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer. <i>Experimental Cell Research</i> , 2020, 396, 112282.	1.2	28
15	Role of Complementary and Alternative Medicine in Prevention and Treatment of COVID-19: An Overhyped Hope. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 565-567.	0.7	33
16	Cancer Researchers in Time of the Coronavirus Pandemic: A Time to Repurpose and Rethink. <i>Asian Pacific Journal of Cancer Care</i> , 2020, 5, 161-163.	0.0	2
17	Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. <i>Translational Lung Cancer Research</i> , 2019, 8, S106-S121.	1.3	62
18	Environmental and occupational determinants of lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S31-S49.	1.3	76

#	ARTICLE	IF	CITATIONS
19	Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells. <i>Molecular Oncology</i> , 2019, 13, 480-494.	2.1	16
20	WNT5A as a therapeutic target in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 767-778.	2.7	47
21	Cancer research in India: Challenges & opportunities. <i>Indian Journal of Medical Research</i> , 2018, 148, 362.	0.4	41
22	Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. <i>PLoS ONE</i> , 2017, 12, e0184418.	1.1	58
23	Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. <i>Oncotarget</i> , 2017, 8, 71471-71488.	0.8	29
24	Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion. <i>Oncotarget</i> , 2016, 7, 37790-37802.	0.8	23
25	WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 144.	3.5	48
26	Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-lipoxygenase and induces differentiation of colon cancer cells. <i>Molecular Oncology</i> , 2016, 10, 1415-1429.	2.1	47
27	Dual mechanisms of action of the RNA-binding protein human antigen R explains its regulatory effect on melanoma cell migration. <i>Translational Research</i> , 2016, 172, 45-60.	2.2	19
28	Abstract A116: Targeting the Wnt-5a signaling pathway as a novel anti-metastatic therapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, A116-A116.	1.9	6
29	Therapy for BRAF-Resistant Melanomas: Is WNT5A the Answer?. <i>Cancers</i> , 2015, 7, 1900-1924.	1.7	18
30	Interleukin-6 drives melanoma cell motility through p38-MAPK-dependent up-regulation of WNT5A expression. <i>Molecular Oncology</i> , 2014, 8, 1365-1378.	2.1	53
31	WNT5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. <i>Molecular Oncology</i> , 2013, 7, 870-883.	2.1	38
32	Fas-FasL System in Molar Pregnancy. <i>American Journal of Reproductive Immunology</i> , 2011, 65, 512-520.	1.2	2
33	Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines. <i>Chemico-Biological Interactions</i> , 2010, 183, 455-461.	1.7	26
34	Apoptosis and Bcl-2 Protein Expression in Human Placenta over the Course of Normal Pregnancy. <i>Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia</i> , 2010, 39, 426-431.	0.3	12
35	Expression analysis of E-cadherin, Slug and GSK3 β in invasive ductal carcinoma of breast. <i>BMC Cancer</i> , 2009, 9, 325.	1.1	103
36	Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/ β -catenin signaling. <i>Chemico-Biological Interactions</i> , 2009, 181, 263-271.	1.7	149

#	ARTICLE	IF	CITATIONS
37	Clinical significance of promoter hypermethylation of RASSF1A, RAR β 2, BRCA1 and HOXA5 in breast cancers of Indian patients. Life Sciences, 2008, 82, 1288-1292.	2.0	26
38	Epigenetic alterations of CDH1 and APC genes: Relationship with activation of Wnt/ β -catenin Pathway in invasive ductal carcinoma of breast. Life Sciences, 2008, 83, 318-325.	2.0	86
39	Wnt Signaling Pathway in Invasive Ductal Carcinoma of the Breast: Relationship between β -Catenin, Disheveled and Cyclin D1 Expression. Oncology, 2007, 73, 112-117.	0.9	74
40	Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sciences, 2007, 80, 1873-1881.	2.0	90
41	Promoter hypermethylation of TMS1, BRCA1, ER α and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sciences, 2007, 81, 280-287.	2.0	101
42	Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Research and Treatment, 2007, 104, 277-286.	1.1	45
43	The Hedgehog Signaling Pathway in Breast Cancer. International Journal of Clinical Reviews, 0, , .	0.1	0